title: Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
abstract: Cannabinoid hyperemesis syndrome (CHS) is a rare clinical syndrome characterised by nausea, cyclic vomiting and severe abdominal pain in association with chronic cannabis use. It is often under-recognised or misdiagnosed, resulting in the unnecessary workup and frequent hospitalisations. Long-term treatment of CHS is abstinence from cannabis, but acute symptomatic management has been a struggle for many clinicians. The present report highlights the use of haloperidol as an agent that successfully and safely treats the unrelenting symptoms of CHS.
authors.affiliation: New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA.
authors.forename: Faisal
authors.initials: F
authors.lastname: Inayat
authors.affiliation: Mount Sinai St. Luke's Hospital, Icahn School of Medicine, New York, New York, USA.
authors.forename: Hafeez Ul Hassan
authors.initials: HU
authors.lastname: Virk
authors.affiliation: University of Arizona, Tucson, Arizona, USA.
authors.forename: Waqas
authors.initials: W
authors.lastname: Ullah
authors.affiliation: Shifa International Hospital, Islamabad, Pakistan.
authors.forename: Qulsoom
authors.initials: Q
authors.lastname: Hussain
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000627:therapeutic use*; D002186:Cannabinoids / Q000009:adverse effects*; D006220:Haloperidol / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000150:complications*; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy; D013577:Syndrome; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000932:Antiemetics; D002186:Cannabinoids; D006220:Haloperidol